Evidence map›Paper›PMID 34458837›Full record

ArticleRSC chemical biology2021

Deciphering the substrate recognition mechanisms of the heparan sulfate 3-

Rylee Wander, Andrea M Kaminski, Yongmei Xu, Vijayakanth Pagadala, Juno M Krahn, Truong Quang Pham, Jian Liu, Lars C Pedersen

Open access · goldAbstract read
In one paragraph

Article in RSC chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Synthetic biology for heparin biomanufacturing.Bioresources and bioprocessing · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Structural glycobiology - from enzymes to organelles.Biochemical Society transactions · 2025
    Review
  7. Increased 3-Science advances · 2023
    Article
  8. Review
  9. Review
  10. Emerging chemical and biochemical tools for studying 3-American journal of physiology. Cell physiology · 2022
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Rylee WanderDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina Chapel Hill North Carolina USA jian_liu@unc.edu.ORCID https://orcid.org/0000-0002-4158-7384
Andrea M KaminskiGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health Research Triangle Park North Carolina USA.ORCID https://orcid.org/0000-0002-6263-4186
Yongmei XuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina Chapel Hill North Carolina USA jian_liu@unc.edu.
Vijayakanth PagadalaGlycan Therapeutics Raleigh North Carolina USA.ORCID https://orcid.org/0000-0001-7349-4230
Juno M KrahnGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health Research Triangle Park North Carolina USA.
Truong Quang PhamGlycan Therapeutics Raleigh North Carolina USA.
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina Chapel Hill North Carolina USA jian_liu@unc.edu.ORCID https://orcid.org/0000-0001-8552-1400
Lars C PedersenGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health Research Triangle Park North Carolina USA.ORCID https://orcid.org/0000-0002-4488-4077
National Institutes of Health · USUniversity of North Carolina at Chapel Hill · USGlycoMira Therapeutics (United States) · US

Funding

Development of dekaparin to replace animal-sourced heparinR44HL139187 · NHLBI · GLYCAN THERAPEUTICS CORPORATION · PI PAGADALA, VIJAYAKANTH · 2019 to 2025
$4.2M
Synthesis and Pharmacological Evaluation of Homogenous Ultra-Low Molecular Weight HeparinsR01HL144970 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN · 2019 to 2021
$946k
Quantitative analysis of heparan sulfate using 13C-labeled standardsR43GM142304 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI PAGADALA, VIJAYAKANTH · 2021 to 2021
$300k
NHLBI NIH HHS R01 HL144970NHLBI NIH HHS R44 HL139187NIGMS NIH HHS R43 GM142304
6 · The paper itself

Abstract

The sulfation at the 3-OH position of a glucosamine saccharide is a rare modification, but is critically important for the biological activities of heparan sulfate polysaccharides. Heparan sulfate 3-

Identifiers

PMID34458837
PMCPMC8341778
OpenAlexW3171487399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.